Navigation Links
AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedy's Disease)
Date:1/25/2011

SAN DIEGO, Jan. 25, 2011 /PRNewswire/ -- AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).  Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar muscular atrophy (SBMA) or Kennedy's Disease, a rare hereditary neurodegenerative disease, which currently has no approved drug available to patients.  Key pathological features of SBMA include progressive motor neuropathy and androgen insensitivity syndrome caused by a distinctive mutation within the androgen receptor (AR) gene.  ASC has developed a unique platform of therapeutic small molecule drugs, which selectively and potently enhance degradation of the AR protein, termed AR degradation enhancers (ARD enhancers).

"Given encouraging pre-clinical results and the clear need for a new therapeutic option for SBMA patients, ASC is excited to continue advancing preclinical development of this promising novel drug candidate," said ASC President Charles Shih, Ph.D. "The funding provided by the NINDS/NIH will significantly propel our efforts in validating ARD enhancers as a disease-modifying therapeutic intervention against such a rare and devastating neurodegenerative illness."

This $3.8 Million cooperative translational research grant will leverage expertise from the NINDS and draw upon ASC's innovative approach to targeting the mutant androgen receptor (AR).  The goals of the grant will be to first validate an orally administered ARD enhancer drug is efficacious in the SBMA transgenic animal model, and further, to complete preclinical toxicology, safety pharmacology, and ADME studies necessary in supporting of an IND filing to commence human clinical studies.  To date, ASC has provided robust proof of concept data using an ARD enhancer compound; demonstrating treatment ameliorates cardinal features of SBMA neuromuscular pathology, restores functional activity, and improves survival in a SBMA transgenic mouse model.

About Spinal Bulbar Muscular Atrophy (SBMA) – Kennedy's DiseaseSpinal and bulbar muscular atrophy (SBMA or Kennedy's Disease) is a rare hereditary neurodegenerative disease that affects lower motor neurons, with progressive muscle atrophy and weakness of the bulbar, facial, and limb muscles. The disease results in progressive dysphasia, motor dysfunction, and typically affects men in the fourth or fifth decade of life.  SBMA is caused by a mutation in the X-chromosome linked androgen receptor (AR) gene that results in excessive repeats of the amino acid glutamine (polyQ) within AR protein.  A molecular genetic test is clinically available which has a 100% mutation detection rate to definitively diagnose SBMA.  Neurotoxicity caused by these expanded polyQ AR aggregates is believed to play a pivotal role in the pathogenesis of SBMA.  SBMA is considered an orphan drug indication and no approved therapy exists.  Furthermore, very few drug candidates are being evaluated in clinical trials.  

About AndroScience CorporationAndroScience (ASC) is a privately held San Diego, California based pharmaceutical company applying expertise in natural product chemistry to develop proprietary small molecule drug compounds targeting disease dependent intracellular signaling events related to the Androgen Receptor (AR) and selective Signal Transducer and Activation of Transcription (STAT) pathways.  The company is focused on therapeutic indications of significant medical and commercial importance, including androgen-dependent diseases in both topical and systemic treatment settings and novel approaches to the treatment of cancer.  Active ARD enhancer therapeutic programs include topical indications: acne (in Phase 2b clinical trail), alopecia (male pattern baldness) and wound healing;  and systemic indications: SBMA, prostate cancer, HBV-induced HCC, and bladder cancer. Currently, the newly discovered STAT inhibitor compounds demonstrate potent anti-tumor properties across a wide range of solid and hematological tumors.  ASC is actively seeking licensing partners for multiple products at various stages of program development with both domestic and international based pharmaceutical companies.

www.androscience.com

About National Institute of Neurological Disorders and Stroke (NINDS), NIHThe Intramural Research Program of the National Institute of Neurological Disorders and Stroke (NINDS) is one of the largest neuroscience research centers in the world. Investigators in the NINDS intramural program conduct research in the basic, translational, and clinical neurosciences. Their specific interests cover a broad range of neuroscience research including molecular biophysics, synapses and circuits, neuronal development, integrative neuroscience, brain imaging and neurological disorders. Through collaboration, pre- and postdoctoral training programs, jointly sponsored seminar series and special interest groups, NINDS investigators and investigators in other intramural programs (NIMH, NEI, NIDCD and NICHD) contribute to a vital and growing neuroscience research community at the National Institutes of Health.

www.ninds.nih.govFor more information, contact AndroScience CorporationAddress: AndroScience™ Corporation11175 Flintkote Ave., Ste. FSan Diego, CA 92121Phone: (858) 638-7230General Inquiries: info88@androscience.comBusiness Development Inquiries: bnewcomer@androscience.com
'/>"/>

SOURCE AndroScience Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AndroScience Corporation Forms Strategic Alliance With Taiwan Based Orient Europharma to Develop Novel Topical Acne Therapeutic
2. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
3. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
4. Celsion Corporation Announces Completion of $5.1 Million Registered Direct Offering
5. CVS Caremark Corporation to Hold Fourth Quarter 2010 Conference Call
6. Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare
7. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
8. Luminex Corporation Fourth Quarter and Full Year 2010 Earnings Release Scheduled for February 7, 2011
9. Kensey Nash Corporation Announces Its Second Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
10. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
11. TREVENTIS Corporation Founder Wins Prestigious Discovery Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):